Cytek Biosciences (CTKB) AI Stock Analysis

• Market Cap: $511.44M
• Dividend Yield: N/A
• Average Volume (3M): 1.13M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.73
• Revenue Growth: -0.85%
• EPS Growth: 61.31%
• Country: US
• Employees: 663
• Sector: Healthcare
• Sector Strength: 52
• Industry: Medical - Devices
• EPS (TTM): -0.04
• Shares Outstanding: 127,223,780
• 10 Day Avg. Volume: 1,037,391
• 30 Day Avg. Volume: 1,127,617
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.40
• Enterprise Value/Revenue: 1.04
• Enterprise Value/Gross Profit: 1.91
• Enterprise Value/Ebitda: -23.92
• 1Y Price Target: $5.00
• Price Target Upside: 21.95% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

• Rating: 55 Neutral
• Price Target: $4.00 ▼(-2.44% Downside)

Cytek Biosciences' overall stock score is primarily influenced by its financial performance challenges, including declining revenue and profitability. Technical analysis provides some support with short-term bullish indicators, but valuation concerns due to negative earnings and lack of dividends weigh heavily. The earnings call highlights both opportunities in recurring revenue growth and challenges in overall revenue decline, contributing to a mixed outlook.

Positive Factors

Market Opportunities

The launch of the Cytek Aurora Evo system, with improvements tailored to the pharma end market, presents new opportunities.

Platform Adoption

Cytek Cloud continues to demonstrate strong workflow enablement, supporting increased adoption and utilization of the FSP platform.

Recurring Revenue Growth

Recurring revenue maintained positive momentum, with both services and consumables growing 18% year over year.

Negative Factors

Instrument Demand

Instrument demand remains muted due to policy and macro headwinds.

Market Contraction

The flow cytometry market may be contracting or at least stagnating, making FY25 a difficult year to operate.

Revenue Challenges

Upside to near-term estimates is limited due to an instrument-heavy revenue mix and a second half-weighted revenue cadence.

Cytek Biosciences Business Overview & Revenue Model

Company Description

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

How the Company Makes Money

Cytek Biosciences generates revenue primarily through the sale of its flow cytometry systems, which include hardware, software, and associated reagents. The company offers a range of products tailored to different research and clinical needs, allowing it to cater to a wide customer base, including academic institutions, pharmaceutical companies, and clinical research organizations. In addition to product sales, Cytek may also derive income from service contracts, maintenance agreements, and training programs. Strategic partnerships and collaborations with other companies and research institutions can further contribute to its earnings by expanding its market reach and driving product innovation.

Cytek Biosciences Financial Statement Overview

Summary

Cytek Biosciences is experiencing challenges with declining revenue and profitability, as reflected in the income statement. The balance sheet remains strong with low leverage, but the negative return on equity highlights profitability issues. Cash flow management appears efficient, though growth is a concern. Overall, the company needs to address revenue growth and profitability to improve its financial health.

Income Statement

Cytek Biosciences has experienced a significant decline in revenue growth, with a TTM revenue growth rate of -51.5%. The company is currently operating at a loss, as indicated by negative net profit and EBIT margins. However, the gross profit margin remains relatively stable at 54.4%, suggesting some operational efficiency.

Balance Sheet

The company's balance sheet shows a low debt-to-equity ratio of 0.037, indicating minimal leverage and financial risk. However, the return on equity is negative, reflecting the company's current unprofitability. The equity ratio is strong, suggesting a solid capital structure.

Cash Flow

Cash flow analysis reveals a decline in free cash flow growth by 36.9% in the TTM period. The operating cash flow to net income ratio is positive, indicating some cash generation capability despite net losses. The free cash flow to net income ratio is relatively high, suggesting efficient cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	196.03M	200.45M	193.01M	164.04M	127.95M	92.84M
Gross Profit	106.68M	111.11M	109.43M	100.97M	79.14M	51.71M
EBITDA	-8.51M	-10.03M	-4.41M	9.54M	10.40M	15.37M
Net Income	-6.40M	-6.02M	-12.15M	2.58M	4.42M	19.41M
Balance Sheet
Total Assets	493.32M	499.50M	494.46M	519.48M	463.70M	219.98M
Cash, Cash Equivalents and Short-Term Investments	262.02M	277.86M	262.41M	341.15M	364.62M	165.23M
Total Debt	14.12M	17.02M	14.14M	18.09M	0.00	2.77M
Total Liabilities	115.76M	103.76M	101.39M	93.93M	56.90M	236.01M
Stockholders Equity	377.56M	395.74M	393.06M	425.30M	406.46M	-16.03M
Cash Flow
Free Cash Flow	11.06M	21.85M	454.00K	-22.10M	266.00K	13.61M
Operating Cash Flow	15.20M	25.38M	5.28M	-12.23M	4.63M	15.16M
Investing Cash Flow	-86.20M	-82.97M	-93.89M	-55.91M	-20.99M	-1.55M
Financing Cash Flow	-29.87M	-15.82M	-41.81M	5.51M	213.56M	122.61M

Cytek Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTKB, the sentiment is Positive. The current price of 4.1 is above the 20-day moving average (MA) of 4.05, above the 50-day MA of 3.74, and below the 200-day MA of 4.46, indicating a neutral trend. The MACD of 0.09 indicates Positive momentum. The RSI at 57.05 is Neutral, neither overbought nor oversold. The STOCH value of 47.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTKB.

Cytek Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTKB	55 Neutral	$511.44M	―	-1.67%	―	-0.85%	61.31%
Sector *	51 Neutral	$7.95B	-0.38	-43.43%	2.22%	22.30%	-1.83%
MASS	50 Neutral	$196.31M	―	-46.85%	―	14.65%	-86.36%
BFLY	49 Neutral	$392.72M	―	-29.42%	―	23.13%	46.62%
TLSI	47 Neutral	$248.84M	―	271.41%	―	45.50%	53.07%
SGHT	47 Neutral	$193.24M	―	-57.10%	―	-3.89%	9.68%
PACB	46 Neutral	$381.47M	―	-189.52%	―	-17.35%	-19.34%

Cytek Biosciences Corporate Events

Cytek Biosciences Elects New Directors at Annual Meeting

On June 18, 2025, Cytek Biosciences held its annual meeting of stockholders, with approximately 81.4% of outstanding shares represented. During the meeting, Richard Chin, MD, and Deborah Neff were elected as Class I directors to serve until 2028. Additionally, the executive compensation for 2024 was approved, and Deloitte & Touche LLP was ratified as the independent registered public accounting firm for 2025.